Meeting
2018 ASCO Annual Meeting
Phase I/II study to evaluate the safety and efficacy of tenalisib, a novel PI3K δ/γ dual inhibitor in combination with pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma.
Authors
Rod Ramchandren
Barbara Ann Karmanos Cancer Institute, Detroit, MI
Rod Ramchandren , Ryan C Lynch , Prajak J. Barde , Ajit Nair
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Hodgkin Lymphoma
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS7584)
DOI
10.1200/JCO.2018.36.15_suppl.TPS7584
Abstract #
TPS7584
Poster Bd #
219b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Robert J. Motzer
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015.
First Author: Deirdre Jill Cohen
Poster
2020 ASCO Virtual Scientific Program
Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.
First Author: Petri Bono
Poster
2019 ASCO Annual Meeting
A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.
First Author: Shubham Pant